Simplement Spółka z Ograniczoną Odpowiedzialnością (KRS 0000236444, NIP 1181800146) is a Polish company, headquartered in Janów, Mazowieckie voivodeship. SIMPLEMENT operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since June 20, 2005. SIMPLEMENT's most recently reported net revenue was 0 PLN for 2024.
No reported revenue
The company reported no revenue in any available reporting year. This may indicate a non-operating entity.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Simplement
Identity
- Name
- Simplement Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- June 20, 2005
- Registry status as of
- May 14, 2026
- Latest entry
- May 14, 2026
- Founding act
- 09.05.2011 ROK. REPERTORIUM A NR 1234/2011 KANCELARIA NOTARIALNA MAŁGORZATA TOMCZYK - PERŁOWSKA NOTARIUSZ UL.WARSZAWSKA …
Articles of association history (3)
- REPERTORIUM A NR 4290/2005, 17 MAJA 2005 ROKU, NOTARIUSZ IWONA BOGUSŁAWSKA W KANCELARII W WARSZAWIE PRZY UL.STAWKI NR 2
- May 9, 2011: 09.05.2011 ROK. REPERTORIUM A NR 1234/2011 KANCELARIA NOTARIALNA MAŁGORZATA TOMCZYK - PERŁOWSKA NOTARIUSZ UL.WARSZAWSKA 189, BABICE NOWE, 05-082 STARE BABICE ZMIANA PARAGRAFU 6 UMOWY SPÓŁKI
- October 23, 2014: AKTEM NOTARIALNYM Z DNIA 23.10.2014 R., REP. A NR 1922/2014 SPORZĄDZONYM PRZEZ NOTARIUSZA MAŁGORZATĘ TOMCZYK-PERŁOWSKĄ PROWADZĄCĄ KANCELARIĘ NOTARIALNĄ W NOWYCH BABICACH PRZY UL. WARSZAWSKIEJ 189 ( 05-082 STARE BABICE), ZMIENIONE ZOSTAŁY § 2 ORAZ § 3 UMOWY SPÓŁKI.
Activities
Main activity
72.11.ZResearch and experimental development on biotechnology
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- GEN. SIKORSKIEGO, 74, 05-082, JANÓW, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- WARSZAWSKI ZACHODNI
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
Risk and payment profile - Simplement
Credibility rating
61 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
5
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/21 yrs
Board changes
0
0/21 yrs
PKD changes
2
2/21 yrs
Name changes
1
1/21 yrs
Data from 21 years of registry activity.
Credibility history
Payment reliability score from 2019–2024
Current: C (61/100)
Trend: improving (+3.7 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2019–2024
Current: 9.7 K PLN
Safe: 4.4 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Simplement
Founded
June 20, 2005
20 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
JANÓW
MAZOWIECKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
50.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Filed years
5 years
2019–2024 · profitable: 0/5
Registry entries
38
latest: May 14, 2026
Revenue
0 PLN
2024
Net profit
0 PLN
2024
Assets
69.5 K PLN
2024
Equity
53.0 K PLN
2024
EBITDA
0 PLN
2024
Valuation
39.0 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Simplement.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
